| n | TTP analysis | OS analysis | ||
---|---|---|---|---|---|
 |  | Hazard ratio (95% CI) | Log-rank P -value | Hazard ratio (95% CI) | Log-rank P -value |
Baseline characteristics | |||||
Age†| 37 | 0.984 (0.944-1.02) | 0.429 | 0.996 (0.962-1.03) | 0.819 |
Sex (male vs. female) | 37 (34 vs. 3) | 0.214 (0.028-1.64) | 0.105 | 0.654 (0.155-2.76) | 0.559 |
Number of disease sites (1 vs. ≥ 2) | 37 (18 vs. 19) | 1.78 (0.754-4.18) | 0.183 | 1.03 (0.501-2.11) | 0.939 |
Cirrhosis (no vs. yes) | 35 (23 vs. 12) | 2.22 (0.907-5.41) | 0.0743 | 2.23 (0.975-5.11) | 0.0521 |
Portal vein thrombosis (no vs. yes) | 37 (18 vs. 19) | 1.3 (0.549-3.1) | 0.547 | 2.00 (0.938-4.27) | 0.0682 |
Hepatitis B (no vs. yes) | 32 (15 vs. 7) | 1.74 (0.685-4.4) | 0.240 | 1.07 (0.489-2.35) | 0.864 |
Histological grade (low or medium vs. high) | 33 (22 vs. 11) | 0.756 (0.276-2.07) | 0.586 | 0.78 (0.337-1.81) | 0.561 |
Child-Pugh class (A vs. B) | 37 (31 vs. 6) | 1.49 (0.428-5.18) | 0.530 | 3.39 (1.34-8.61) | 0.0065* |
ECOG PS (0 vs. 1) | 37 (19 vs. 18) | 3.21 (1.19-8.63) | 0.0157* | 7.86 (2.78-22.2) | < 0.0001* |
CLIP stage (≤ 2 vs. > 2) | 27 (15 vs. 12) | 1.57 (0.490-5.00) | 0.445 | 1.23 (0.54-2.81) | 0.62 |
Soluble proteins | |||||
Baseline VEGF-A (ng/mL)†| 37 | 0.041 (0.0006-3.00) | 0.132 | 1.04 (0.056-19.4) | 0.977 |
Baseline VEGF-C (ng/mL)†| 37 | 0.413 (0.196-0.869) | 0.0165* | 0.683 (0.384-1.21) | 0.190 |
Baseline sVEGFR-2 (ng/mL)†| 37 | 0.887 (0.699-1.13) | 0.325 | 0.969 (0.803-1.17) | 0.746 |
Baseline sKIT (ng/mL)†| 37 | 0.996 (0.959-1.04) | 0.853 | 0.997 (0.970-1.02) | 0.804 |
sVEGFR-2 ratio to baseline at C1D28†| 28 | 0.216 (0.0084-5.54) | 0.353 | 0.049 (0.0027-0.672) | 0.0253* |